Mechanism of factor VIIa-dependent coagulation in hemophilia blood

Blood

Volumn 99, Issue 3, 2002, Pages 923-930

  Butenas, Saulius ^a   Brummel, Kathleen E ^a   Branda, Richard F ^a   Paradis, Sara G ^a   Mann, Kenneth G ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; FIBRINOPEPTIDE; THROMBIN; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD CLOTTING; CASE REPORT; CONTROLLED STUDY; DRUG EFFICACY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 0036464599     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.923     Document Type: Article

References (65)

1. Coagulation cascade: An overview
2. Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants
3. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder
4. Factor VII deficiency
5. Hemophilia A
6. Acquired factor IX deficiency. A report of two cases
7. A concentrate of human antihaemophilic factor - Its use in six cases of haemophilia
8. Evaluation of a new concentrate for the treatment of factor IX deficiency
9. Hepatitis, epidemiology and liver function in hemophiliacs in Sweden
10. Factor IX concentrates for clinical use
11. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States
12. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody
13. Clinical experience of a new monoclonal antibody purified factor IX: Half-life, recovery, and safety in patients with hemophilia B
14. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
15. A multi-center study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
16. Recombinant factor IX
17. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
18. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice
19. Post-translational modifications of recombinant myotube-synthesized factor IX
20. Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector
21. Gene therapy: A 2001 perspective
22. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies
23. Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors
24. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate
25. Considerations for the hemophiliac patient with inhibitors to factor VIII
26. The use of human factor VIIa in the treatment of two hemophilia patients with high-titer inhibitors
27. Successful use of recombinant FVIIa in a patient with severe haemophilia A during synovectomy
28. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors
29. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
30. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors
31. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa
32. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors
33. Recombinant activated factor VII as a universal haemostatic agent
34. Platelet activity of high-dose factor VIIa is independent of tissue factor
35. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII
36. A model for the tissue factor pathway to thrombin. I. An empirical study
37. A model for the tissue factor pathway to thrombin. II. A mathematical simulation
38. Blood clotting in minimally altered whole blood
39. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases
40. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II
41. Blood coagulation in hemophilia A and hemophilia C
42. A simplified procedure for purification of human prothrombin, factor IX and factor X
43. Isolation of functional human coagulation factor V by using a hybridoma antibody
44. Reactive site peptide structural similarity between heparin co-factor II and antithrombin III
45. Preparation of suspension of washed platelets from humans
46. Extrinsic pathway proteolytic activity
47. An integrated study of fibrinogen during blood coagulation
48. Detection of factor VIII inhibitors with the partial thromboplastin time
49. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy
50. Platelets and phospholipids in tissue factor-initiated thrombin generation
51. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: Effects of calcium, phospholipids, and tissue factor
52. Recombinant FVIIa in the treatment of warfarin bleeding
53. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors
54. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease
55. Recombinant factor VIIa for the treatment of congenital factor VII deficiency
56. Recombinant factor VIIa treatment of bleeding associated with acute renal failure
57. New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: Recombinant active factor VII concentrate
58. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis
59. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders
60. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium
61. Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: Advantages of administration by continuous infusion over bolus intermittent injections
62. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
63. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness
64. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa
65. Thresholds for thrombin functions during tissue factor-induced blood coagulation